Biophytis SA is a clinical-stage biotechnology company focused on the development of pharmacological solutions for age-related diseases. Founded in 2006 and headquartered in Paris, France, the company is listed on NASDAQ under the ticker BPTSY and on Euronext Growth in Paris. Biophytis specializes in therapies aimed at improving mobility and functional capacity in older adults, addressing conditions that currently lack approved treatments.
The company’s lead candidate, Sarconeos (BIO101), is a selective activator of the MAS receptor designed to combat sarcopenia and muscle weakness. Sarconeos has progressed through Phase II and Phase III clinical trials, with data indicating potential benefits in improving muscle strength and physical performance in elderly patients. In parallel, Biophytis is advancing an ophthalmology program targeting age-related macular degeneration and other retinal diseases, with preclinical studies supporting its approach to preserving visual function.
Biophytis operates research facilities in France and maintains a subsidiary in the United States to support its clinical trial activities and regulatory engagements. The company collaborates with academic institutions and contract research organizations across Europe and North America, leveraging specialized expertise in geriatric medicine, pharmacology and translational research. These partnerships help streamline clinical development and facilitate patient recruitment for multicenter trials.
Under the leadership of Chief Executive Officer Pascal Brand-Williams, Biophytis is guided by a scientific advisory board comprised of experts in muscle biology, ophthalmology and geriatrics. The company’s mission is to deliver safe and effective therapies that address unmet medical needs in an aging population, with the long-term goal of enhancing healthspan and quality of life worldwide.
AI Generated. May Contain Errors.
